IL165816A0 - Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia - Google Patents

Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia

Info

Publication number: IL165816A0
Authority: IL; Israel
Prior art keywords: neoplasia; treatment; cyclooxygenase; medicament; inhibitors
Prior art date: 1996-10-15

Application number

IL16581604A

Other languages

English (en)

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-15

Filing date

2004-12-16

Publication date

2006-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21843754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL165816(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-16 Application filed by Searle & Co filed Critical Searle & Co

2006-01-15 Publication of IL165816A0 publication Critical patent/IL165816A0/xx

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
230000009826 neoplastic cell growth Effects 0.000 title abstract 2
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
230000002265 prevention Effects 0.000 title 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyridine Compounds (AREA)

IL16581604A 1996-10-15 2004-12-16 Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia IL165816A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2849496P	1996-10-15	1996-10-15
PCT/US1997/018670 WO1998016227A1 (en)	1996-10-15	1997-10-14	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Publications (1)

Publication Number	Publication Date
IL165816A0 true IL165816A0 (en)	2006-01-15

Family

ID=21843754

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL12856897A IL128568A0 (en)	1996-10-15	1997-10-14	Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
IL15450197A IL154501A0 (en)	1996-10-15	1997-10-14	Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
IL16581604A IL165816A0 (en)	1996-10-15	2004-12-16	Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
IL12856897A IL128568A0 (en)	1996-10-15	1997-10-14	Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
IL15450197A IL154501A0 (en)	1996-10-15	1997-10-14	Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia

Country Status (24)

Country	Link
EP (3)	EP0932402B1 (xx)
JP (1)	JP2001503395A (xx)
KR (1)	KR20000049138A (xx)
CN (2)	CN100558356C (xx)
AT (2)	ATE271385T1 (xx)
AU (1)	AU742645B2 (xx)
BR (1)	BR9712314A (xx)
CA (1)	CA2267186C (xx)
CZ (1)	CZ298022B6 (xx)
DE (2)	DE69738815D1 (xx)
DK (2)	DK0932402T3 (xx)
ES (2)	ES2224222T3 (xx)
HU (1)	HU227564B1 (xx)
IL (3)	IL128568A0 (xx)
NO (1)	NO326822B1 (xx)
NZ (3)	NZ506515A (xx)
PT (2)	PT932402E (xx)
RO (1)	RO120172B1 (xx)
RU (1)	RU2239429C2 (xx)
SK (1)	SK284788B6 (xx)
TR (1)	TR199900827T2 (xx)
TW (1)	TWI235060B (xx)
UA (1)	UA67732C2 (xx)
WO (1)	WO1998016227A1 (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2223154A1 (en)	1995-06-02	1996-12-05	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en)	1998-09-14	2003-01-28	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US20040072889A1 (en)	1997-04-21	2004-04-15	Pharmacia Corporation	Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6887893B1 (en)	1997-12-24	2005-05-03	Sankyo Company, Limited	Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6294558B1 (en)	1999-05-31	2001-09-25	Pfizer Inc.	Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en)	1998-06-11	2004-04-27	Pfizer Inc.	Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040053900A1 (en) *	1998-12-23	2004-03-18	Pharmacia Corporation	Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20020103141A1 (en) *	1998-12-23	2002-08-01	Mckearn John P.	Antiangiogenic combination therapy for the treatment of cancer
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
IL143870A0 (en) *	1998-12-23	2002-04-21	Searle & Co	Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) *	1998-12-23	2004-06-24	Pharmacia Corporation	Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6649645B1 (en) *	1998-12-23	2003-11-18	Pharmacia Corporation	Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
DE60041808D1 (de) *	1999-01-27	2009-04-30	Cornell Res Foundation Inc	Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs
NZ515711A (en) *	1999-06-24	2004-01-30	Pharmacia Corp	Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
AU775305B2 (en) *	1999-07-29	2004-07-29	Tularik Inc.	Combination therapy using pentafluorobenzenesulfonamide and platin compound
KR20020050294A (ko)	1999-11-22	2002-06-26	피터 기딩스	신규화합물
WO2001054688A1 (en) *	2000-01-28	2001-08-02	Merck & Co., Inc.	Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
GB0003224D0 (en)	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
GB0005357D0 (en)	2000-03-06	2000-04-26	Smithkline Beecham Plc	Compounds
US20020009421A1 (en) *	2000-06-01	2002-01-24	Wilder Karol J.	Therapy following skin injury from exposure to ultraviolet radiation
GB0021494D0 (en)	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
KR20030030027A (ko)	2000-09-21	2003-04-16	스미스클라인비이참피이엘시이	Ｒａｆ 키나제 저해제인 이미다졸 유도체
WO2002039958A2 (en)	2000-11-03	2002-05-23	Tularik Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US7183316B2 (en)	2001-05-03	2007-02-27	Cornell Research Foundation, Inc.	Treatment of HPV caused diseases
GB0112348D0 (en)	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
GB0112810D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112802D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0119477D0 (en)	2001-08-09	2001-10-03	Glaxo Group Ltd	Pyrimidine derivatives
AR038957A1 (es)	2001-08-15	2005-02-02	Pharmacia Corp	Terapia de combinacion para el tratamiento del cancer
MXPA04003878A (es) *	2001-10-25	2004-07-08	Novartis Ag	Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.
FR2835433B1 (fr) *	2002-02-01	2006-02-17	Richard Lab M	Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2
CN1642926A (zh) *	2002-03-15	2005-07-20	法玛西雅公司	结晶帕瑞考昔钠
AR039391A1 (es)	2002-04-08	2005-02-16	Glaxo Group Ltd	Compuesto de ciclopenteno, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
WO2004018452A1 (en)	2002-08-19	2004-03-04	Glaxo Group Limited	Pyrimidine derivatives as selective cox-2 inhibitors
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
KR100484525B1 (ko) *	2002-10-15	2005-04-20	씨제이 주식회사	이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
GB0225548D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Compounds
PE20040844A1 (es)	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
EP1611112B1 (en) *	2003-02-11	2012-08-22	Vernalis (Cambridge) Limited	Isoxazole compounds as inhibitors of heat shock proteins
GB0308466D0 (en)	2003-04-11	2003-05-21	Novartis Ag	Organic compounds
EP1919882A2 (en)	2005-02-17	2008-05-14	Synta Pharmaceuticals Corporation	Isoxazole combretastatin derivatives for the treatment of proliferative disorders
EP1858507B1 (en) *	2005-03-08	2012-11-28	Mitsui Norin Co., Ltd	Polyphenol coxib combinations and methods
CU23511B6 (es) *	2006-02-28	2010-04-13	Biorec B V	Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
KR20100122513A (ko) *	2008-07-17	2010-11-22	아사히 가세이 파마 가부시키가이샤	질소 함유 복소환 화합물
TW201020547A (en) *	2008-08-22	2010-06-01	Novartis Ag	Use of a COX-2 inhibitor for the treatment of a COX-2 dependent disorder in a patient not carrying HLA alleles associated with hepatotoxicity
WO2017004274A2 (en)	2015-06-29	2017-01-05	Nantbioscience, Inc.	Compositions and methods of rit1 inhibition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU33730B (en)	1967-04-18	1978-02-28	Farmaceutici Italia	Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en)	1976-01-15	1977-03-15	Stanford Research Institute	Synthesis of adriamycin and 7,9-epiadriamycin
ATE167473T1 (de) *	1990-08-20	1998-07-15	Eisai Co Ltd	Sulfonamid-derivate
DE69224839T2 (de)	1991-07-19	1998-10-08	Monsanto Co	Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2293952A1 (en)	1993-01-15	1994-07-21	David B. Reitz	Preparation of esters and analogs thereof
US5409944A (en)	1993-03-12	1995-04-25	Merck Frosst Canada, Inc.	Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en)	1993-05-13	1994-11-24	Jacques Yves Gauthier	2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en)	1993-05-21	1995-01-10	Monsanto Company	2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
CA2146961C (en) *	1993-09-10	2006-11-07	Hiroshi Yoshino	Heterobicyclic sulfonamide and sulfonic ester derivatives
US5344991A (en)	1993-10-29	1994-09-06	G.D. Searle & Co.	1,2 diarylcyclopentenyl compounds for the treatment of inflammation
KR100263817B1 (ko) *	1993-11-30	2000-08-16	윌리암스 로저 에이	염증치료용 치환 피라졸일벤젠술폰아미드
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5475018A (en)	1993-11-30	1995-12-12	G. D. Searle & Co.	1,5-diphenyl pyrazole compounds for treatment of inflammation
US5434178A (en) *	1993-11-30	1995-07-18	G.D. Searle & Co.	1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5393790A (en)	1994-02-10	1995-02-28	G.D. Searle & Co.	Substituted spiro compounds for the treatment of inflammation
US5486534A (en)	1994-07-21	1996-01-23	G. D. Searle & Co.	3,4-substituted pyrazoles for the treatment of inflammation
AU3201095A (en)	1994-07-27	1996-02-22	G.D. Searle & Co.	Substituted thiazoles for the treatment of inflammation
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5739166A (en)	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
US5686470A (en)	1995-02-10	1997-11-11	Weier; Richard M.	2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en)	1995-02-10	1997-01-21	G. D. Searle & Co.	3,4-Diaryl substituted pyridines for the treatment of inflammation
WO1996025405A1 (en)	1995-02-13	1996-08-22	G.D. Searle & Co.	Substituted isoxazoles for the treatment of inflammation
US5510368A (en)	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
CA2223154A1 (en) *	1995-06-02	1996-12-05	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1997008174A1 (en)	1995-08-31	1997-03-06	Smithkline Beecham Corporation	Interleukin converting enzyme and apoptosis
PT780386E (pt)	1995-12-20	2003-02-28	Hoffmann La Roche	Inibidores de metaloprotease de matriz

1997
- 1997-10-14 CN CNB2005100062282A patent/CN100558356C/zh not_active Expired - Fee Related
- 1997-10-14 ES ES97911746T patent/ES2224222T3/es not_active Expired - Lifetime
- 1997-10-14 HU HU9904221A patent/HU227564B1/hu not_active IP Right Cessation
- 1997-10-14 EP EP97911746A patent/EP0932402B1/en not_active Expired - Lifetime
- 1997-10-14 NZ NZ506515A patent/NZ506515A/en not_active IP Right Cessation
- 1997-10-14 EP EP08159064A patent/EP1977749A1/en not_active Withdrawn
- 1997-10-14 NZ NZ334921A patent/NZ334921A/en not_active IP Right Cessation
- 1997-10-14 JP JP51859198A patent/JP2001503395A/ja not_active Ceased
- 1997-10-14 WO PCT/US1997/018670 patent/WO1998016227A1/en not_active Ceased
- 1997-10-14 CA CA002267186A patent/CA2267186C/en not_active Expired - Fee Related
- 1997-10-14 CZ CZ0117199A patent/CZ298022B6/cs not_active IP Right Cessation
- 1997-10-14 RU RU99110192/15A patent/RU2239429C2/ru not_active IP Right Cessation
- 1997-10-14 IL IL12856897A patent/IL128568A0/xx not_active IP Right Cessation
- 1997-10-14 CN CNB971987548A patent/CN1332661C/zh not_active Expired - Fee Related
- 1997-10-14 BR BR9712314-5A patent/BR9712314A/pt not_active Application Discontinuation
- 1997-10-14 KR KR1019990703225A patent/KR20000049138A/ko not_active Withdrawn
- 1997-10-14 ES ES04011516T patent/ES2308068T3/es not_active Expired - Lifetime
- 1997-10-14 DE DE69738815T patent/DE69738815D1/de not_active Expired - Lifetime
- 1997-10-14 PT PT97911746T patent/PT932402E/pt unknown
- 1997-10-14 AT AT97911746T patent/ATE271385T1/de active
- 1997-10-14 PT PT04011516T patent/PT1479385E/pt unknown
- 1997-10-14 SK SK462-99A patent/SK284788B6/sk not_active IP Right Cessation
- 1997-10-14 EP EP04011516A patent/EP1479385B1/en not_active Expired - Lifetime
- 1997-10-14 UA UA99052704A patent/UA67732C2/uk unknown
- 1997-10-14 AT AT04011516T patent/ATE399547T1/de active
- 1997-10-14 AU AU49048/97A patent/AU742645B2/en not_active Ceased
- 1997-10-14 DE DE69729946T patent/DE69729946T2/de not_active Expired - Lifetime
- 1997-10-14 RO RO99-00418A patent/RO120172B1/ro unknown
- 1997-10-14 TW TW090122228A patent/TWI235060B/zh not_active IP Right Cessation
- 1997-10-14 DK DK97911746T patent/DK0932402T3/da active
- 1997-10-14 DK DK04011516T patent/DK1479385T3/da active
- 1997-10-14 IL IL15450197A patent/IL154501A0/xx not_active IP Right Cessation
- 1997-10-14 TR TR1999/00827T patent/TR199900827T2/xx unknown
1999
- 1999-04-15 NO NO19991793A patent/NO326822B1/no not_active IP Right Cessation
2001
- 2001-02-07 NZ NZ509755A patent/NZ509755A/xx not_active IP Right Cessation
2004
- 2004-12-16 IL IL16581604A patent/IL165816A0/xx unknown

Also Published As

Publication number	Publication date
NZ334921A (en)	2001-03-30
CN1332661C (zh)	2007-08-22
RO120172B1 (ro)	2005-10-28
BR9712314A (pt)	1999-08-31
NO991793D0 (no)	1999-04-15
ATE399547T1 (de)	2008-07-15
PT932402E (pt)	2004-11-30
CA2267186C (en)	2002-05-14
CA2267186A1 (en)	1998-04-23
CN100558356C (zh)	2009-11-11
TWI235060B (en)	2005-07-01
EP0932402B1 (en)	2004-07-21
AU742645B2 (en)	2002-01-10
NZ506515A (en)	2002-05-31
HUP9904221A2 (hu)	2000-09-28
CZ117199A3 (cs)	1999-07-14
EP1977749A1 (en)	2008-10-08
PT1479385E (pt)	2008-09-02
IL128568A0 (en)	2000-01-31
UA67732C2 (uk)	2004-07-15
DK0932402T3 (da)	2004-11-08
EP0932402A1 (en)	1999-08-04
DE69729946T2 (de)	2005-01-20
HUP9904221A3 (en)	2000-12-28
CN1244122A (zh)	2000-02-09
TR199900827T2 (xx)	1999-07-21
CN1660083A (zh)	2005-08-31
ES2308068T3 (es)	2008-12-01
RU2239429C2 (ru)	2004-11-10
IL154501A0 (en)	2003-09-17
DE69729946D1 (de)	2004-08-26
AU4904897A (en)	1998-05-11
DE69738815D1 (de)	2008-08-14
EP1479385A1 (en)	2004-11-24
SK284788B6 (sk)	2005-11-03
KR20000049138A (ko)	2000-07-25
DK1479385T3 (da)	2008-08-04
ES2224222T3 (es)	2005-03-01
ATE271385T1 (de)	2004-08-15
SK46299A3 (en)	2000-03-13
WO1998016227A1 (en)	1998-04-23
NO326822B1 (no)	2009-02-23
HU227564B1 (en)	2011-08-29
EP1479385B1 (en)	2008-07-02
NO991793L (no)	1999-04-15
HK1025518A1 (en)	2000-11-17
JP2001503395A (ja)	2001-03-13
CZ298022B6 (cs)	2007-05-30
NZ509755A (en)	2002-09-27

Publication	Publication Date	Title
IL154501A0 (en)	2003-09-17	Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
IL123002A0 (en)	1998-08-16	1-Phenyl-2- phenylacetoxy- ethanone derivatives
IL175398A0 (en)	2006-09-05	Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
GR3033127T3 (en)	2000-08-31	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
LU91145I9 (xx)	2018-12-28
RU2088589C1 (en)	1997-08-27	Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
IL162214A0 (en)	2005-11-20	Pyridine derivatives and pharmaceutical compositions containing the same
SI0934065T1 (sl)	2007-02-28	Novi kriptoficinski derivati kot anti-neoplasticna sredstva
ZA941464B (en)	1994-09-27	Use of pregnane derivative
CA2289017A1 (en)	1998-12-03	The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
CA2301590A1 (en)	1999-03-25	2-aminopyridines as inhibitors of cyclooxygenase-2
IL156140A0 (en)	2003-12-23	Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
IL158900A0 (en)	2004-05-12	Pharmaceutical compositions containing a tricyclic compound for the prevention or treatment of skin diseases
MY138319A (en)	2009-05-29	1,5-benzodiazepine derivatives